Loading…

Re-designing environmentally persistent pharmaceutical pollutant through programmed inactivation: The case of methotrexate

Environmental emission of pharmaceutical pollutants notably causes the contamination of aquatic ecosystems and drinking water. Typically, reduction of these pollutants in the environment is mostly managed by ameliorated wastewater treatments. Here, we report a method for the eco-design of drugs thro...

Full description

Saved in:
Bibliographic Details
Published in:Chemosphere (Oxford) 2022-11, Vol.306, p.135616-135616, Article 135616
Main Authors: Espinosa, Anaïs, Rascol, Estelle, Abellán Flos, Marta, Skarbek, Charles, Lieben, Pascale, Bannerman, Eva, Martinez, Alba Diez, Pethe, Stéphanie, Benoit, Pierre, Nélieu, Sylvie, Labruère, Raphaël
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c439t-831aa1083d1f33f224e878543b47978fb6f4219d2fefbbd0a3d705c9762e807b3
cites cdi_FETCH-LOGICAL-c439t-831aa1083d1f33f224e878543b47978fb6f4219d2fefbbd0a3d705c9762e807b3
container_end_page 135616
container_issue
container_start_page 135616
container_title Chemosphere (Oxford)
container_volume 306
creator Espinosa, Anaïs
Rascol, Estelle
Abellán Flos, Marta
Skarbek, Charles
Lieben, Pascale
Bannerman, Eva
Martinez, Alba Diez
Pethe, Stéphanie
Benoit, Pierre
Nélieu, Sylvie
Labruère, Raphaël
description Environmental emission of pharmaceutical pollutants notably causes the contamination of aquatic ecosystems and drinking water. Typically, reduction of these pollutants in the environment is mostly managed by ameliorated wastewater treatments. Here, we report a method for the eco-design of drugs through the introduction within the molecular structure of a sensitive chemical group responsive to water treatments. The new drugs are thus programmed to fragment more easily and quickly than the original drugs. In this “retro catabolic drug design” strategy, methotrexate was used as drug model and an ether analog displaying a similar pharmacological profile was selected. Using photo-irradiation experiments at 254 nm, a representative drinking water treatment process, the identified transformation products were predominantly obtained from the expected molecular scission. Moreover, a faster kinetics of degradation was measured for the ether analog as compared to methotrexate and its transformation products were far less cytotoxic. [Display omitted] •The strategy of “retro catabolic drug design” is disclosed for the programmed/improved inactivation of drugs.•The drug model is methotrexate and three analogs were synthesized.•An ether analog displaying similar antitumor activity was selected and its better human metabolic stability was demonstrated.•Using photo-irradiation, the identified transformation products were mostly obtained from the expected molecular scission.•A faster kinetics of degradation was measured for the ether analog and its transformation products were less cytotoxic.
doi_str_mv 10.1016/j.chemosphere.2022.135616
format article
fullrecord <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_03826123v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0045653522021099</els_id><sourcerecordid>2688088685</sourcerecordid><originalsourceid>FETCH-LOGICAL-c439t-831aa1083d1f33f224e878543b47978fb6f4219d2fefbbd0a3d705c9762e807b3</originalsourceid><addsrcrecordid>eNqNkU-P0zAQxS0EYsvCdzA3OKT4T5zY3FbVwiJVQkLL2XKccePKiYPtVCyfnlRBiCOn0cy89zSjH0JvKdlTQpsP570dYIx5HiDBnhHG9pSLhjbP0I7KVlWUKfkc7QipRdUILm7Qq5zPhKxmoV6iGy4kJVKoHfr1Daoesj9NfjphmC4-xWmEqZgQnvAMKftc1hbPg0mjsbAUb03AcwxhKWZdlCHF5TTgOcVTMuMIPfaTscVfTPFx-ogfB8DWZMDR4RHKEEuCn6bAa_TCmZDhzZ96i75_un88PFTHr5-_HO6Ola25KpXk1Jj1Wt5Tx7ljrAbZSlHzrm5VK13XuJpR1TMHrut6YnjfEmFV2zCQpO34LXq_5Q4m6Dn50aQnHY3XD3dHfZ0RLllDGb_QVftu067f_FggFz36bCEEM0FcsmaNlETKRopVqjapTTHnBO5vNiX6ikmf9T-Y9BWT3jCt3sPmhfXvi4eks_UwWeh9Alt0H_1_pPwGcDGicw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2688088685</pqid></control><display><type>article</type><title>Re-designing environmentally persistent pharmaceutical pollutant through programmed inactivation: The case of methotrexate</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Espinosa, Anaïs ; Rascol, Estelle ; Abellán Flos, Marta ; Skarbek, Charles ; Lieben, Pascale ; Bannerman, Eva ; Martinez, Alba Diez ; Pethe, Stéphanie ; Benoit, Pierre ; Nélieu, Sylvie ; Labruère, Raphaël</creator><creatorcontrib>Espinosa, Anaïs ; Rascol, Estelle ; Abellán Flos, Marta ; Skarbek, Charles ; Lieben, Pascale ; Bannerman, Eva ; Martinez, Alba Diez ; Pethe, Stéphanie ; Benoit, Pierre ; Nélieu, Sylvie ; Labruère, Raphaël</creatorcontrib><description>Environmental emission of pharmaceutical pollutants notably causes the contamination of aquatic ecosystems and drinking water. Typically, reduction of these pollutants in the environment is mostly managed by ameliorated wastewater treatments. Here, we report a method for the eco-design of drugs through the introduction within the molecular structure of a sensitive chemical group responsive to water treatments. The new drugs are thus programmed to fragment more easily and quickly than the original drugs. In this “retro catabolic drug design” strategy, methotrexate was used as drug model and an ether analog displaying a similar pharmacological profile was selected. Using photo-irradiation experiments at 254 nm, a representative drinking water treatment process, the identified transformation products were predominantly obtained from the expected molecular scission. Moreover, a faster kinetics of degradation was measured for the ether analog as compared to methotrexate and its transformation products were far less cytotoxic. [Display omitted] •The strategy of “retro catabolic drug design” is disclosed for the programmed/improved inactivation of drugs.•The drug model is methotrexate and three analogs were synthesized.•An ether analog displaying similar antitumor activity was selected and its better human metabolic stability was demonstrated.•Using photo-irradiation, the identified transformation products were mostly obtained from the expected molecular scission.•A faster kinetics of degradation was measured for the ether analog and its transformation products were less cytotoxic.</description><identifier>ISSN: 0045-6535</identifier><identifier>EISSN: 1879-1298</identifier><identifier>DOI: 10.1016/j.chemosphere.2022.135616</identifier><identifier>PMID: 35810859</identifier><language>eng</language><publisher>Elsevier Ltd</publisher><subject>Chemical Sciences ; Eco-design ; Environmental Engineering ; Environmental Sciences ; Medicinal Chemistry ; Pharmaceutical pollutants ; Photodegradation ; Retro catabolic drug design ; Structural identification</subject><ispartof>Chemosphere (Oxford), 2022-11, Vol.306, p.135616-135616, Article 135616</ispartof><rights>2022 Elsevier Ltd</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c439t-831aa1083d1f33f224e878543b47978fb6f4219d2fefbbd0a3d705c9762e807b3</citedby><cites>FETCH-LOGICAL-c439t-831aa1083d1f33f224e878543b47978fb6f4219d2fefbbd0a3d705c9762e807b3</cites><orcidid>0000-0003-3683-2768 ; 0000-0002-3677-7300 ; 0000-0002-2301-6107 ; 0000-0003-0054-2064</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://hal.science/hal-03826123$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Espinosa, Anaïs</creatorcontrib><creatorcontrib>Rascol, Estelle</creatorcontrib><creatorcontrib>Abellán Flos, Marta</creatorcontrib><creatorcontrib>Skarbek, Charles</creatorcontrib><creatorcontrib>Lieben, Pascale</creatorcontrib><creatorcontrib>Bannerman, Eva</creatorcontrib><creatorcontrib>Martinez, Alba Diez</creatorcontrib><creatorcontrib>Pethe, Stéphanie</creatorcontrib><creatorcontrib>Benoit, Pierre</creatorcontrib><creatorcontrib>Nélieu, Sylvie</creatorcontrib><creatorcontrib>Labruère, Raphaël</creatorcontrib><title>Re-designing environmentally persistent pharmaceutical pollutant through programmed inactivation: The case of methotrexate</title><title>Chemosphere (Oxford)</title><description>Environmental emission of pharmaceutical pollutants notably causes the contamination of aquatic ecosystems and drinking water. Typically, reduction of these pollutants in the environment is mostly managed by ameliorated wastewater treatments. Here, we report a method for the eco-design of drugs through the introduction within the molecular structure of a sensitive chemical group responsive to water treatments. The new drugs are thus programmed to fragment more easily and quickly than the original drugs. In this “retro catabolic drug design” strategy, methotrexate was used as drug model and an ether analog displaying a similar pharmacological profile was selected. Using photo-irradiation experiments at 254 nm, a representative drinking water treatment process, the identified transformation products were predominantly obtained from the expected molecular scission. Moreover, a faster kinetics of degradation was measured for the ether analog as compared to methotrexate and its transformation products were far less cytotoxic. [Display omitted] •The strategy of “retro catabolic drug design” is disclosed for the programmed/improved inactivation of drugs.•The drug model is methotrexate and three analogs were synthesized.•An ether analog displaying similar antitumor activity was selected and its better human metabolic stability was demonstrated.•Using photo-irradiation, the identified transformation products were mostly obtained from the expected molecular scission.•A faster kinetics of degradation was measured for the ether analog and its transformation products were less cytotoxic.</description><subject>Chemical Sciences</subject><subject>Eco-design</subject><subject>Environmental Engineering</subject><subject>Environmental Sciences</subject><subject>Medicinal Chemistry</subject><subject>Pharmaceutical pollutants</subject><subject>Photodegradation</subject><subject>Retro catabolic drug design</subject><subject>Structural identification</subject><issn>0045-6535</issn><issn>1879-1298</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNqNkU-P0zAQxS0EYsvCdzA3OKT4T5zY3FbVwiJVQkLL2XKccePKiYPtVCyfnlRBiCOn0cy89zSjH0JvKdlTQpsP570dYIx5HiDBnhHG9pSLhjbP0I7KVlWUKfkc7QipRdUILm7Qq5zPhKxmoV6iGy4kJVKoHfr1Daoesj9NfjphmC4-xWmEqZgQnvAMKftc1hbPg0mjsbAUb03AcwxhKWZdlCHF5TTgOcVTMuMIPfaTscVfTPFx-ogfB8DWZMDR4RHKEEuCn6bAa_TCmZDhzZ96i75_un88PFTHr5-_HO6Ola25KpXk1Jj1Wt5Tx7ljrAbZSlHzrm5VK13XuJpR1TMHrut6YnjfEmFV2zCQpO34LXq_5Q4m6Dn50aQnHY3XD3dHfZ0RLllDGb_QVftu067f_FggFz36bCEEM0FcsmaNlETKRopVqjapTTHnBO5vNiX6ikmf9T-Y9BWT3jCt3sPmhfXvi4eks_UwWeh9Alt0H_1_pPwGcDGicw</recordid><startdate>20221101</startdate><enddate>20221101</enddate><creator>Espinosa, Anaïs</creator><creator>Rascol, Estelle</creator><creator>Abellán Flos, Marta</creator><creator>Skarbek, Charles</creator><creator>Lieben, Pascale</creator><creator>Bannerman, Eva</creator><creator>Martinez, Alba Diez</creator><creator>Pethe, Stéphanie</creator><creator>Benoit, Pierre</creator><creator>Nélieu, Sylvie</creator><creator>Labruère, Raphaël</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><orcidid>https://orcid.org/0000-0003-3683-2768</orcidid><orcidid>https://orcid.org/0000-0002-3677-7300</orcidid><orcidid>https://orcid.org/0000-0002-2301-6107</orcidid><orcidid>https://orcid.org/0000-0003-0054-2064</orcidid></search><sort><creationdate>20221101</creationdate><title>Re-designing environmentally persistent pharmaceutical pollutant through programmed inactivation: The case of methotrexate</title><author>Espinosa, Anaïs ; Rascol, Estelle ; Abellán Flos, Marta ; Skarbek, Charles ; Lieben, Pascale ; Bannerman, Eva ; Martinez, Alba Diez ; Pethe, Stéphanie ; Benoit, Pierre ; Nélieu, Sylvie ; Labruère, Raphaël</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c439t-831aa1083d1f33f224e878543b47978fb6f4219d2fefbbd0a3d705c9762e807b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Chemical Sciences</topic><topic>Eco-design</topic><topic>Environmental Engineering</topic><topic>Environmental Sciences</topic><topic>Medicinal Chemistry</topic><topic>Pharmaceutical pollutants</topic><topic>Photodegradation</topic><topic>Retro catabolic drug design</topic><topic>Structural identification</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Espinosa, Anaïs</creatorcontrib><creatorcontrib>Rascol, Estelle</creatorcontrib><creatorcontrib>Abellán Flos, Marta</creatorcontrib><creatorcontrib>Skarbek, Charles</creatorcontrib><creatorcontrib>Lieben, Pascale</creatorcontrib><creatorcontrib>Bannerman, Eva</creatorcontrib><creatorcontrib>Martinez, Alba Diez</creatorcontrib><creatorcontrib>Pethe, Stéphanie</creatorcontrib><creatorcontrib>Benoit, Pierre</creatorcontrib><creatorcontrib>Nélieu, Sylvie</creatorcontrib><creatorcontrib>Labruère, Raphaël</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><jtitle>Chemosphere (Oxford)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Espinosa, Anaïs</au><au>Rascol, Estelle</au><au>Abellán Flos, Marta</au><au>Skarbek, Charles</au><au>Lieben, Pascale</au><au>Bannerman, Eva</au><au>Martinez, Alba Diez</au><au>Pethe, Stéphanie</au><au>Benoit, Pierre</au><au>Nélieu, Sylvie</au><au>Labruère, Raphaël</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Re-designing environmentally persistent pharmaceutical pollutant through programmed inactivation: The case of methotrexate</atitle><jtitle>Chemosphere (Oxford)</jtitle><date>2022-11-01</date><risdate>2022</risdate><volume>306</volume><spage>135616</spage><epage>135616</epage><pages>135616-135616</pages><artnum>135616</artnum><issn>0045-6535</issn><eissn>1879-1298</eissn><abstract>Environmental emission of pharmaceutical pollutants notably causes the contamination of aquatic ecosystems and drinking water. Typically, reduction of these pollutants in the environment is mostly managed by ameliorated wastewater treatments. Here, we report a method for the eco-design of drugs through the introduction within the molecular structure of a sensitive chemical group responsive to water treatments. The new drugs are thus programmed to fragment more easily and quickly than the original drugs. In this “retro catabolic drug design” strategy, methotrexate was used as drug model and an ether analog displaying a similar pharmacological profile was selected. Using photo-irradiation experiments at 254 nm, a representative drinking water treatment process, the identified transformation products were predominantly obtained from the expected molecular scission. Moreover, a faster kinetics of degradation was measured for the ether analog as compared to methotrexate and its transformation products were far less cytotoxic. [Display omitted] •The strategy of “retro catabolic drug design” is disclosed for the programmed/improved inactivation of drugs.•The drug model is methotrexate and three analogs were synthesized.•An ether analog displaying similar antitumor activity was selected and its better human metabolic stability was demonstrated.•Using photo-irradiation, the identified transformation products were mostly obtained from the expected molecular scission.•A faster kinetics of degradation was measured for the ether analog and its transformation products were less cytotoxic.</abstract><pub>Elsevier Ltd</pub><pmid>35810859</pmid><doi>10.1016/j.chemosphere.2022.135616</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0003-3683-2768</orcidid><orcidid>https://orcid.org/0000-0002-3677-7300</orcidid><orcidid>https://orcid.org/0000-0002-2301-6107</orcidid><orcidid>https://orcid.org/0000-0003-0054-2064</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0045-6535
ispartof Chemosphere (Oxford), 2022-11, Vol.306, p.135616-135616, Article 135616
issn 0045-6535
1879-1298
language eng
recordid cdi_hal_primary_oai_HAL_hal_03826123v1
source ScienceDirect Freedom Collection 2022-2024
subjects Chemical Sciences
Eco-design
Environmental Engineering
Environmental Sciences
Medicinal Chemistry
Pharmaceutical pollutants
Photodegradation
Retro catabolic drug design
Structural identification
title Re-designing environmentally persistent pharmaceutical pollutant through programmed inactivation: The case of methotrexate
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T16%3A38%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Re-designing%20environmentally%20persistent%20pharmaceutical%20pollutant%20through%20programmed%20inactivation:%20The%20case%20of%20methotrexate&rft.jtitle=Chemosphere%20(Oxford)&rft.au=Espinosa,%20Ana%C3%AFs&rft.date=2022-11-01&rft.volume=306&rft.spage=135616&rft.epage=135616&rft.pages=135616-135616&rft.artnum=135616&rft.issn=0045-6535&rft.eissn=1879-1298&rft_id=info:doi/10.1016/j.chemosphere.2022.135616&rft_dat=%3Cproquest_hal_p%3E2688088685%3C/proquest_hal_p%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c439t-831aa1083d1f33f224e878543b47978fb6f4219d2fefbbd0a3d705c9762e807b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2688088685&rft_id=info:pmid/35810859&rfr_iscdi=true